Norman M. Kaplan
About
In The Last Decade
Norman M. Kaplan
314 papers receiving 10.3k citations
Hit Papers
Peers
Comparison fields: 5 of 225
- Cardiology and Cardiovascular Medicine 3.3k
- Endocrinology, Diabetes and Metabolism 3.3k
- Surgery 1.3k
- Physiology 1.2k
- Molecular Biology 1.1k
Countries citing papers authored by Norman M. Kaplan
This map shows the geographic impact of Norman M. Kaplan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Norman M. Kaplan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Norman M. Kaplan more than expected).
Fields of papers citing papers by Norman M. Kaplan
This network shows the impact of papers produced by Norman M. Kaplan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Norman M. Kaplan. The network helps show where Norman M. Kaplan may publish in the future.
Co-authorship network of co-authors of Norman M. Kaplan
This figure shows the co-authorship network connecting the top 25 collaborators of Norman M. Kaplan. A scholar is included among the top collaborators of Norman M. Kaplan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Norman M. Kaplan. Norman M. Kaplan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | Southwestern internal medicine conference | 3 |
| 2 | Microvascular decompression: Hype or hoax? | 2 |
| 3 | 41 | |
| 4 | 8 | |
| 5 | The sixth report of the Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure | 28 |
| 6 | 30 | |
| 7 | 5 | |
| 8 | Changing hypertension treatment to reduce the overall cardiovascular risk. | 6 |
| 9 | 1 | |
| 10 | 1 | |
| 11 | 2 | |
| 12 | Calcium and potassium in the treatment of essential hypertension. | 2 |
| 13 | 8 | |
| 14 | Effects of atenolol, nadolol and propranolol on renal haemodynamics | 2 |
| 15 | Moderate sodium restriction in the treatment of hypertension | 2 |
| 16 | Assessment of blood pressure control during once-a-day administration of antihypertensive drugs | 3 |
| 17 | Assessment of 24 hr blood pressure control during once a day administration of antihypertensive therapy | 6 |
| 18 | Alpha- and beta-receptor blocking drugs in the treatment of hypertension. | 5 |
| 19 | Diuretics and sodium restriction in the treatment of hypertension: effects on potassium wastage and blood pressure control | 0 |
| 20 | Comparison of Aldactazide and Dyazide for hypertension | 7 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.